Good
Mostly Aligned
Patient Risk:
Low
Summary
The provided content cites multiple FDA label excerpts (HPA axis suppression, dosing limits, occlusion caution, pediatric risk, and Cushing’s syndrome) supporting the endocrine/systemic absorption concept. However, no specific AI-generated claim text was actually provided to audit, limiting verification to the stated supported/contradicted determinations rather than line-by-line claim alignment.
Category Scores
Accurate Statements
Clobetasol propionate is shown to suppress the HPA axis at doses as low as 2 grams per day, and systemic absorption can produce reversible HPA axis suppression with potential for clinical glucocorticoid insufficiency during treatment or upon withdrawal.
SECTION 5.1 Effects on the Endocrine System
Use of topical corticosteroids may require periodic evaluation for HPA axis suppression; risk factors include more potent steroids, large surface area, prolonged use, occlusion, altered skin barrier, and liver failure.
SECTION 5.1 Effects on the Endocrine System
Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can result from systemic absorption of topical corticosteroids.
SECTION 5.1 Effects on the Endocrine System
Treatment beyond 2 consecutive weeks is not recommended and total dosage should not exceed 50 g/week because of potential for HPA axis suppression.
SECTION 1 Indications and Usage
Clobetasol propionate cream USP 0.05% (emollient) treatment should be limited to 2 consecutive weeks and amounts greater than 50 grams per week should not be used.
SECTION 2 Dosage and Administration
Clobetasol propionate cream should not be used with occlusive dressings.
SECTION 2 Dosage and Administration
Pediatric patients under 12 years of age: use is not recommended, and pediatric patients are at greater risk of HPA axis suppression and Cushing's syndrome; also greater risk of glucocorticosteroid insufficiency during or after withdrawal.
SECTION 8.4 Pediatric Use
Cushing's syndrome has been reported in infants and adults as a result of prolonged use of topical clobetasol propionate formulations.
SECTION 6 Adverse Reactions
Unsupported Statements
Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids.
No unsupported content was found; however, this statement is only present within the provided label-citation text in the prompt and not as an auditable AI claim. No separate AI-generated claim text was provided to verify directly.
Contradictions
Important Omissions
No actual AI-generated claim(s) were provided for line-by-line verification; therefore, potential omissions in the AI response specific to the user’s claim cannot be assessed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
All substantive points included in the prompt are consistent with the provided FDA label excerpts regarding systemic absorption, HPA axis suppression, related endocrine effects, dosing limits, occlusion avoidance, pediatric risk, and reported Cushing’s syndrome with prolonged use. Main limitation is lack of auditable AI claim text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
No specific AI claim text was provided; alignment is inferred from the quoted label-citation content rather than directly audited AI statements.
Suggested Improvement
Provide the exact AI-generated sentences to be audited so each claim can be mapped precisely to the relevant FDA label language and omissions can be evaluated relative to that claim.